# Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer

> **NCT00429299** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 121 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib
- **BIOLOGICAL:** trastuzumab
- **DRUG:** paclitaxel
- **DRUG:** fluorouracil
- **DRUG:** epidoxorubicin
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00429299
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2016-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00429299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00429299, "Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00429299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*